)
AstraZeneca Pharma India has hit the upper circuit filter of 20% at Rs 1,113 on the National Stock Exchange (NSE), after its Sweden-based parent company AstraZeneca Pharmaceuticals AB suggested that it plans to delist company’s equity shares from the Indian stock exchanges.
The board of directors of AstraZeneca Pharma India is scheduled to meet on Wednesday March 05, 2014 to consider the delisting proposal.
On March 01, 2014, the company received a letter from its parent and promoter, proposing to make a voluntary delisting offer to the public shareholders of the company, AstraZeneca Pharma India said in a statement.
The pharmaceutical company’s shares are currently listed on the Bombay Stock Exchange (BSE), National Stock Exchange of India (NSE) and Bangalore Stock Exchange Limited (BgSE).
AstraZeneca Pharmaceuticals AB holds 18.75 million equity shares or 75% of the total paid-up share capital of the company.
A combined around 26,000 shares have already changed hands on the counter and there are pending buy orders for nearly 65,000 shares on the NSE and BSE at 0920 hours.
The board of directors of AstraZeneca Pharma India is scheduled to meet on Wednesday March 05, 2014 to consider the delisting proposal.
On March 01, 2014, the company received a letter from its parent and promoter, proposing to make a voluntary delisting offer to the public shareholders of the company, AstraZeneca Pharma India said in a statement.
The pharmaceutical company’s shares are currently listed on the Bombay Stock Exchange (BSE), National Stock Exchange of India (NSE) and Bangalore Stock Exchange Limited (BgSE).
AstraZeneca Pharmaceuticals AB holds 18.75 million equity shares or 75% of the total paid-up share capital of the company.
A combined around 26,000 shares have already changed hands on the counter and there are pending buy orders for nearly 65,000 shares on the NSE and BSE at 0920 hours.
